Fact Sheet | Pricing

Part B International Drug Pricing Model for Medicare Part B Drugs

Fact Sheet | Pricing

Part B International Drug Pricing Model for Medicare Part B Drugs

The International Pricing Index (IPI) Model would initially focus on Part B single source drugs, biologicals, and biosimilars that encompass a high percentage of Part B drug utilization and spending. The CMS Innovation Center would test this model under section 1115A of the Social Security Act (the Act), which authorizes testing models expected to reduce program expenditures, while preserving or enhancing the quality of care furnished to beneficiaries. The model under consideration would include physicians, hospitals, and potentially other providers and suppliers in selected geographic areas.

Download the fact sheet

Advertisements

Related Articles | Pricing

Blog | Managed Care

State public option efforts waiver in face of the COVID-19 pandemic

HFMA's Chad Mulvany says although COVID-19 may have "dampened enthusiasm" for Washington state's public option, he is not sure the blame for its slow start rests solely, or even partly, on COVID-19.

News | Coronavirus

HFMA recommended coronavirus resources

The coronavirus is affecting the healthcare industry in unprecedented ways, and HFMA wants to help you stay up to date on the latest news about the outbreak. Come back to this page regularly for coronavirus resources, selected specifically for healthcare finance professionals, including Medicare information on regulations and guidelines, COVID-19 test pricing, COVID-19 coding, telehealth billing FAQs and more.

Blog | Innovation and Disruption

Is another health plan featuring virtual PCPs as primary access point a sign of things to come?

HFMA's Chad Mulvany questions if the recent expansion of telehealth could stimulate a trend of plans offering virtual PCPs as the primary care access point.

Blog | Community Benefit

Strong financial leadership is likely key to the success of accountable communities for health

HFMA's Katie Gilfillan says strong financial leadership is required to manage and source the complex funding and ensure the long-term financial sustainability of accountable communities for health.